```html

Immune Thrombocytopenia (ITP) – A Complete Patient‑Facing Guide

Overview

Immune thrombocytopenia (ITP), formerly called idiopathic thrombocytopenic purpura, is an acquired autoimmune disorder in which the body’s immune system mistakenly attacks and destroys its own platelets. Platelets are tiny blood cells that help clot bleeding; when their numbers fall below normal (< 150,000 per microliter), bleeding can occur even from minor cuts.

Who it affects: ITP can develop at any age, but there are two peaks:

• Children: Approximately 5–9 cases per 100,000 children per year, often after a viral infection.
• Adults: About 3–4 cases per 100,000 adults per year; women are 2‑3 times more likely than men.

Overall, an estimated 60,000‑100,000 people in the United States live with ITP, and the condition is present worldwide with similar incidence rates (CDC, Mayo Clinic).

Symptoms

Because platelet loss can be gradual, many patients experience only subtle signs. However, severe thrombocytopenia (< 20,000/µL) may produce more alarming bleeding. Below is a complete list:

Skin‑related

• Petechiae – tiny, red or purple pinpoint spots that don’t blanch when pressed.
• Ecchymoses – larger bruises that appear with minimal trauma.
• Purpura – larger, raised patches of bleeding under the skin.

Mucosal bleeding

• Bleeding gums or spontaneous bleeding after brushing.
• Nosebleeds (epistaxis) that are frequent or hard to stop.
• Bleeding from the mouth or tongue, especially after dental work.
• Blood in urine (hematuria) or stool (melena/hematochezia) – less common but signals severe thrombocytopenia.

Other manifestations

• Heavy menstrual bleeding (menorrhagia) in women.
• Prolonged bleeding after minor cuts, surgery, or dental procedures.
• Fatigue or light‑headedness (often due to anemia from chronic blood loss).
• Rarely, internal bleeding into joints or muscles causing swelling and pain.

Some individuals, especially children, may be asymptomatic and diagnosed incidentally during routine blood work.

Causes and Risk Factors

ITP is an autoimmune disorder; the exact trigger is often unknown, but several mechanisms and risk factors have been identified:

Immunologic mechanisms

• Auto‑antibodies (IgG) bind to platelet surface antigens (e.g., GPIIb/IIIa), marking them for destruction by splenic macrophages.
• T‑cell dysregulation can suppress platelet production in the bone marrow.
• Cytokine release (e.g., IL‑6, TNF‑α) may worsen platelet clearance.

Potential triggers

• Recent viral infections (e.g., measles, HIV, hepatitis C, SARS‑CoV‑2).
• Vaccinations – rare cases reported after influenza or COVID‑19 vaccines; benefits of vaccination far outweigh the risk.
• Medications such as quinine, sulfonamides, and alpha‑interferon.
• Underlying autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis).
• Chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorders.

Who is at higher risk?

• Women of child‑bearing age (2–3× higher incidence).
• Patients with a personal or family history of other autoimmune diseases.
• Individuals of Asian descent have slightly higher prevalence of chronic ITP, though data vary.

Diagnosis

Diagnosing ITP is largely one of exclusion—ruling out other causes of low platelets.

Initial evaluation

• Complete blood count (CBC) – confirms isolated thrombocytopenia; red and white cell lines are usually normal.
• Peripheral blood smear – visualizes platelet size and excludes clumping or abnormal cells.

Laboratory tests to exclude other conditions

• Coagulation profile (PT/INR, aPTT) – typically normal in ITP.
• Serologies for HIV, hepatitis C, and hepatitis B.
• Antinuclear antibody (ANA) panel if systemic lupus is suspected.
• Thyroid function tests (autoimmune thyroid disease can coexist).

Bone marrow examination

Rarely needed, but may be performed when:

• Platelet count < 10,000/µL with atypical features.
• Patients > 60 years with unexplained cytopenias.

The marrow usually shows normal or increased megakaryocytes, supporting peripheral destruction rather than production failure.

Diagnostic criteria (per American Society of Hematology, 2022)

1. Platelet count < 100,000/µL on at least two separate occasions.
2. Exclusion of other causes (medication, infection, malignancy, inherited thrombocytopenia).
3. Clinical presentation consistent with immune-mediated platelet destruction.

Treatment Options

Treatment is individualized based on platelet count, bleeding severity, patient age, comorbidities, and personal preferences. Observation is acceptable for many adults with platelet counts > 30,000/µL and no bleeding.

First‑line therapies

• Corticosteroids (prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper). Effective in 70–80 % of adults.
• Intravenous immune globulin (IVIG) – rapid rise in platelets within 24–48 h; used for severe bleeding or pre‑procedure preparation.
• Anti‑D immunoglobulin – for Rh‑positive, non‑splenectomized patients; works similarly to IVIG.

Second‑line / steroid‑sparing agents

• Thrombopoietin receptor agonists (TPO‑RAs) – eltrombopag, avatrombopag, romiplostim; stimulate platelet production. Response rates 70‑90 % and can be used long‑term.
• Rituximab – anti‑CD20 monoclonal antibody; depletes B‑cells producing auto‑antibodies. About 40‑60 % achieve durable remission.
• Immunosuppressants – azathioprine, mycophenolate mofetil, cyclosporine; considered when other agents fail.
• Fostamatinib – spleen tyrosine kinase (SYK) inhibitor approved for chronic ITP refractory to first‑line therapy.

Procedural options

• Spleenectomy – historically the most definitive treatment; provides remission in ~65 % of adults but carries surgical risks and lifelong infection risk.
• Splenic artery embolization – minimally invasive alternative for patients who cannot tolerate surgery.

Lifestyle and supportive measures

• Avoid medications that impair platelet function (aspirin, NSAIDs, clopidogrel).
• Use soft toothbrushes and gentle floss to reduce gum bleeding.
• Wear protective gear during high‑impact sports.
• Maintain a balanced diet rich in vitamin K, iron, and folate to support overall hematologic health.

Living with Immune Thrombocytopenia (ITP)

While ITP can be chronic, many patients lead active, fulfilling lives. Practical tips include:

• Regular monitoring – schedule CBC checks every 1‑3 months, or more often when medication changes.
• Vaccinations – stay up‑to‑date, especially pneumococcal and influenza vaccines; consult your provider before live vaccines if on immunosuppressants.
• Travel considerations – carry a medical alert card, a small supply of rescue medication (e.g., oral prednisone), and a copy of recent labs.
• Dental care – inform dentists of your diagnosis; prophylactic IVIG or platelet‑boosting agents may be needed before invasive procedures.
• Pregnancy planning – ITP can worsen during pregnancy; work with a hematologist‑obstetrician team. Most medications (e.g., steroids, IVIG) are safe, while some (e.g., rituximab) are used cautiously.
• Emotional wellbeing – chronic disease can cause anxiety. Support groups, counseling, and patient organizations (e.g., ITP International) are valuable resources.

Prevention

Because ITP is primarily autoimmune, there is no guaranteed way to prevent its onset. However, risk can be lowered by:

• Managing underlying autoimmune disorders promptly.
• Avoiding unnecessary exposure to drugs known to trigger thrombocytopenia.
• Maintaining a healthy immune system through balanced nutrition, regular exercise, adequate sleep, and stress reduction.
• Following infection‑control measures (hand hygiene, vaccinations) to reduce viral triggers linked to acute ITP.

Complications

If left untreated or poorly controlled, ITP can lead to serious outcomes:

• Life‑threatening hemorrhage – intracranial, gastrointestinal, or retinal bleeding.
• Chronic anemia from repeated low‑grade bleeding.
• Splenectomy‑related infections – overwhelming bacterial sepsis, especially from encapsulated organisms.
• Medication side effects – long‑term steroids cause osteoporosis, diabetes, hypertension; immunosuppressants raise infection risk.
• Pregnancy complications – maternal bleeding, fetal thrombocytopenia, or pre‑term delivery.

When to Seek Emergency Care

---

References (accessed April 2026):

1. Mayo Clinic. “Immune thrombocytopenic purpura (ITP)” https://www.mayoclinic.org/diseases‑conditions/immune‑thrombocytopenic‑purpura
2. American Society of Hematology. “Guidelines for the Management of ITP” Blood 2022; 140:1783‑1799.
3. Centers for Disease Control and Prevention. “Thrombocytopenia” https://www.cdc.gov/
4. National Institutes of Health, National Heart, Lung, and Blood Institute. “ITP Fact Sheet” https://www.nhlbi.nih.gov/health/immune-thrombocytopenia
5. World Health Organization. “Bleeding disorders” https://www.who.int/health‑topics/bleeding‑disorders
6. Cleveland Clinic. “Immune Thrombocytopenic Purpura (ITP) Treatment Options” https://my.clevelandclinic.org/health/diseases/17873-immune‑thrombocytopenic‑purpura‑itp

```